Vis enkel innførsel

dc.contributor.authorWu, Carina
dc.contributor.authorWang, Wei
dc.date.accessioned2022-05-02T11:10:07Z
dc.date.available2022-05-02T11:10:07Z
dc.date.created2022-04-08T14:12:48Z
dc.date.issued2022
dc.identifier.issn1999-4923
dc.identifier.urihttps://hdl.handle.net/11250/2993627
dc.description.abstractThe aim of the present study was to systematically examine the effects of variations in the process parameters of the antisolvent precipitation method employed in the preparation of excipient-free pure nanoparticles of five existing/potential psychotropic drugs, namely amitriptyline hydrochloride (AMI), coumarin 6 (COU), curcumin (CUR), nortriptyline hydrochloride (NOR), and prochlorperazine dimaleate (PRO). In the preparation protocols employed, AMI and NOR were expected to be charged enough to be identified as surface-active molecules. Through the employment of five different preparation protocols, the effects of varying the flow rate, the compound concentration in the solvent solution Csolvent0, the solvent:antisolvent ratio (SAS-ratio), and pH of the antisolvent on the final size of the particles DfH were investigated in detail and the results were explained using available theories for the antisolvent precipitation method. We found that DfH increased with the average of the octanol-water partition coefficients (logP)av of the compound. Moreover, the average of the final particle sizes (DfH)av increased linearly with (logP)av. These findings are useful for predicting the size of nanodrugs prepared through the antisolvent precipitation method.en_US
dc.language.isoengen_US
dc.publisherBioMed Centralen_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.titleApplication of Antisolvent Precipitation Method for Formulating Excipient-Free Nanoparticles of Psychotropic Drugsen_US
dc.typeJournal articleen_US
dc.typePeer revieweden_US
dc.description.versionpublishedVersionen_US
dc.rights.holderCopyright 2022 The Author(s)en_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1
dc.identifier.doi10.3390/pharmaceutics14040819
dc.identifier.cristin2016232
dc.source.journalPharmaceuticsen_US
dc.source.pagenumber819en_US
dc.identifier.citationPharmaceutics. 2022, 14 (4), 819.en_US
dc.source.volume14en_US
dc.source.issue4en_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse 4.0 Internasjonal